MedTrace Logo

Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy Caucasians

NCT05005065 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate pharmacokinetics/pharmacodynamics and safety/tolerability of IN-C005 and IN-A001 after oral administration in healthy Caucasian subjects.

Conditions

  • Healthy

Interventions

DRUG

IN-C005 X mg

Oral capsule

DRUG

IN-A001 Y mg

Oral tablet

DRUG

IN-C005 Y mg

Oral capsule

DRUG

IN-C005 Z mg

Oral capsule

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • In-Jin Jang, MD, Ph.D · Clinical Pharmacology and Therapeutics, Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2021-11-18
Completion
2021-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05005065 on ClinicalTrials.gov